Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jung, Hae Won | - |
dc.contributor.author | Kim, Chang-Yeon | - |
dc.contributor.author | Hong, Seung-Pyo | - |
dc.contributor.author | Bae, Han-Joon | - |
dc.contributor.author | Choi, Ji Yong | - |
dc.contributor.author | Ryu, Jae Kean | - |
dc.contributor.author | Lee, Jin-bae | - |
dc.contributor.author | Lee, Kyoung-Hoon | - |
dc.contributor.author | Han, Kyoo-Rok | - |
dc.contributor.author | Yang, Dong-Heon | - |
dc.contributor.author | Park, Chang-Gyu | - |
dc.contributor.author | Yu, Gheol-Woong | - |
dc.contributor.author | Rhee, Moo-Yong | - |
dc.contributor.author | Park, Sung-Ji | - |
dc.contributor.author | Hyon, Min-Su | - |
dc.contributor.author | Shin, Joon-Han | - |
dc.contributor.author | Hong, Bum-Kee | - |
dc.contributor.author | Jin, Han-Young | - |
dc.contributor.author | Lee, Sung-Yun | - |
dc.contributor.author | Seol, Sang-Hoon | - |
dc.contributor.author | Lee, Sang-Rok | - |
dc.contributor.author | Kim, Song-Yi | - |
dc.contributor.author | Lee, Kwang-Je | - |
dc.contributor.author | Cho, Eun-Joo | - |
dc.contributor.author | Nam, Chang-Wook | - |
dc.contributor.author | Park, Tae-Ho | - |
dc.contributor.author | Kim, Ung | - |
dc.contributor.author | Kim, Kee-Sik | - |
dc.date.accessioned | 2024-03-08T08:01:32Z | - |
dc.date.available | 2024-03-08T08:01:32Z | - |
dc.date.issued | 2023-09 | - |
dc.identifier.issn | 1524-6175 | - |
dc.identifier.issn | 1751-7176 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/90584 | - |
dc.description.abstract | The authors performed this study to investigate the efficacy and safety of a rosuvastatin (RSV)/amlodipine (AML) polypill compared with those of atorvastatin (ATV)/AML polypill. We included 259 patients from 21 institutions in Korea. Patients were randomly assigned to 1 of 3 treatment groups: RSV 10 mg/AML 5 mg, RSV 20 mg/AML 5 mg, or ATV 20 mg /AML 5 mg. The primary endpoint was the efficacy of the RSV 10.20 mg/AML 5 mg via percentage changes in LDL-C after 8 weeks of treatment, compared with the ATV 20 mg /AML 5 mg. There was a significant difference in the mean percentage change of LDL-C at 8 weeks between the RSV 10 mg/AML 5 mg and the ATV 20 mg/AML 5 mg (full analysis set [FAS]: -7.08%, 95% CI: -11.79 to -2.38, p = .0034, per-protocol analysis set [PPS]: -6.97%, 95% CI: -11.76 to -2.19, p = .0046). Also, there was a significant difference in the mean percentage change of LDL-C at 8 weeks between the RSV 20 mg/AML 5 mg and the ATV 20 mg/AML 5 mg (FAS: -10.13%, 95% CI: -15.41 to -4.84, p = .0002, PPS: -10.96%, 95% CI: -15.98 to -5.93, p < .0001). There was no significant difference in the adverse events rates between RSV 10 mg/AML 5 mg, RSV 20 mg/AML 5 mg, and ATV 20 mg/AML 5 mg. In conclusion, while maintaining safety, RSV 10 mg/AML 5 mg and the RSV 20 mg/AML 5 mg more effectively reduced LDL-C compared with the ATV 20 mg /AML 5 mg (Clinical trial: NCT03951207). | - |
dc.format.extent | 17 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | WILEY | - |
dc.title | Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia | - |
dc.type | Article | - |
dc.identifier.wosid | 001048755100001 | - |
dc.identifier.doi | 10.1111/jch.14715 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL HYPERTENSION, v.25, no.9, pp 828 - 844 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.scopusid | 2-s2.0-85168126133 | - |
dc.citation.endPage | 844 | - |
dc.citation.startPage | 828 | - |
dc.citation.title | JOURNAL OF CLINICAL HYPERTENSION | - |
dc.citation.volume | 25 | - |
dc.citation.number | 9 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | amlodipine | - |
dc.subject.keywordAuthor | atorvastatin | - |
dc.subject.keywordAuthor | dyslipidemia | - |
dc.subject.keywordAuthor | hypertension | - |
dc.subject.keywordAuthor | rosuvastatin | - |
dc.subject.keywordPlus | BLOOD-PRESSURE | - |
dc.subject.keywordPlus | MYOCARDIAL-INFARCTION | - |
dc.subject.keywordPlus | SINGLE-PILL | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | LIPOPROTEIN(A) | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordPlus | REDUCTION | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | LIPIDS | - |
dc.subject.keywordPlus | TRIAL | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Peripheral Vascular Disease | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.